Plasmin is essential for metalloproteases activation
Introduction
Progression of collagen-induced arthritis (CIA), as well as rheumatoid arthritis (RA) is characterized by pronounced tumor-like expansion of the synovial lining cells, angiogenesis, and infiltration of mononuclear cells resulting in pannus formation, cartilage erosion and ultimately joint destruction. Neovascularization is one of the earliest histopathological findings in RA required for pannus development and trapping of immune cells to the synovium. Thus angiogenesis plays a pivotal role during disease progression. 1, 2 A new therapeutic approach of inflammatory arthritis focuses on angiogenesis inhibition. 3 There are potential mechanisms whereby suppression of blood vessel growth could provide benefit in arthritis by diminishing nutrient supply to the tumor-like synovium, inhibiting leukocyte adhesion and migration through decrease of endothelial cell surface area, and decreasing chemokine and cytokine production by activated endothelial cells.
Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are highly expressed in cultured synoviocytes and in serum from patients with RA. 4 An imbalance in production between angiogenic growth factors (such as FGF and VEGF) and angiogenesis inhibitors (endostatin) would be responsible for angiogenesis in RA. 5 In addition, TNF␣ and soluble E-selectin are also produced in the rheumatoid joint and contribute to vascular proliferation. Therefore, the sustained blockage of the angiogenic process by anti-angiogenic proteins through either conventional drug or local gene delivery systems could inhibit RA progression. Intra-articular administration of a cyclic peptide antagonist of integrin ␣V␤3 to rabbits with antigen-induced arthritis early in disease was associated with a quantitative increase in apoptosis of angiogenic blood vessels, a reduced synovial cell infiltrate, pannus formation and inhibition of synovial angiogenesis. 6 More important in treated animals, however, was the observed decrease in cartilage erosion. A fumagillin derivative AGM-1470, toxic to proliferative endothelial cells, decreased the severity in collageninduced arthritis in rats by reducing VEGF levels. 7, 8 A recent report shows that a monoclonal antibody neutralizing VEGF decreased CIA if injected in the early phase of the disease. 9 All these data argue for a beneficial therapeutic approach targeting angiogenesis in arthritis.
Although its role in the progression of disease remains unknown, urokinase plasminogen activator receptor (uPAR) is expressed by more than 80% of RA synovial cells, 10 and considerable increase of uPA catalytic activity is observed in RA synovium. The uPA/uPAR complex formation at the cell surface is believed to be a critical element in synovial invasiveness, as it controls cell motility, cartilage matrix remodeling and bioavailability of angiogenic factors. The uPA binding to its specific receptor uPAR greatly potentiates plasminogen activation on the cell surface. Generated plasmin is a wide range serine protease which directly degrades some of the components of the extracellular matrix such as fibronectin or laminin, but can also promote local degradation of the stroma by its ability to convert inactive zymogens into active metalloproteases. 11 Furthermore, the uPA/uPAR is also likely involved in neovascularization by promoting endothelial cell migration. 12 Overexpression of uPA/uPAR complex by synoviocytes might then favor cell invasion by this tumor-like mass through the degradation of the cartilage matrix. 13 Therefore, therapeutic molecules aimed at disrupting the uPA/uPAR interaction might be effective by targeting both cell invasiveness and angiogenesis.
The urokinase plasminogen activator (uPA) binds to its receptor uPAR by its light chain fragment, 14 known as amino-terminal fragment (ATF, residues 1-135). This interaction involves the EGF-like domain of ATF and is species-restricted. The ATF lacks the B-chain of uPA, and does not show enzymatic activity. A recombinant adenovirus encoding the non-catalytic ATF of mouse uPA has been previously shown to prevent lung carcinoma metastasis 15 and to protect mice in a liver metastasis model of human colon carcinoma. 16 In these experiments, a marked reduction in the tumoral neovascularization was observed. Because ATF binds to uPAR on cell surfaces, it disrupts the interaction of uPA to its receptor (uPAR) and inhibits uPA/uPAR-dependent angiogenesis process by preventing plasminogen conversion into plasmin, and subsequent activation of the proteolytic cascade required for extracellular matrix degradation and cell invasion. 17 These data prompt us to investigate the protective effect of the murine ATF in a mice model of arthritis.
Gene therapy improves the delivery of therapeutic proteins and allows stable and high concentrations of therapeutic peptides. The potential of Ad5-based vectors to infect a wide range of cells in vivo make them particularly suitable to achieve protection after systemic administration in a systemic disease, such as RA. In the present study, we used a replication-deficient adenovirus vector carrying the murine ATF gene coupled to HSA to improve the half-life of the protein in the circulation, and investigated the therapeutic effect of intravenous delivery on angiogenesis and cartilage degradation in a mice model of arthritis.
Results

Construction of a long-lived chimeric anti-angiogenic protein delivered by a recombinant adenoviral vector
A preliminary study using systemic administration of Ad-mATF in the early phase of joint inflammation showed no effect on disease course (data not shown).
Since the protein was undetectable in the sera of AdmATF-injected animals (data not shown), we constructed a recombinant adenoviral vector expressing murine ATF fused to human serum albumin (HSA) as a way to increase its molecular weight and to prevent clearance by the kidney. 22 
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First, to evaluate the biological activity of the chimeric molecule mATF-HSA, we quantified the inhibition of plasminogen/plasmin activation. The urokinase (uPA) binding to its receptor uPAR induces the conversion of plasminogen into plasmin at the cell surface. ATF can interact with uPAR, but lacking the active site of uPA, it is unable to activate plasminogen into plasmin. In this assay, we evaluated the ATF ability to inhibit endogenous uPA binding to C38 cells, which are known to express abundant uPA and uPAR on their cell surface. C38 cells were infected at different MOI with Ad-mATF-HSA, Ad-mATF and the control Ad-CO1. As shown in Figure 1 , the mATF-HSA hybrid protein expressed from Ad-mATF-HSA can significantly inhibit endogenous uPA activity: 30.9 ± 5.9% plasminogen activation for Ad mATF-HSA infected cells versus 20.8 ± 8.1% with Ad mATF at MOI 100. Thus, genetic coupling to HSA did not significantly reduce the ability of the ATF moiety to interact with its receptor uPAR.
Second, to characterize the expression levels of mATF-HSA after intravenous injection of 10 9 p.f.u. of Ad-mATF-HSA in immunocompetent DBA1 mice, blood samples were collected at 7, 11 and 18 days following adenovirus injection, and assayed by ELISA and immunoprecipitation (Figure 2a and b) . The level of mATF-HSA protein measured in the sera of animals before Ad-mATF-HSA vector injection was not detectable. Both detection techniques revealed that mATF-HSA was undetectable in the control group injected with AdCO1 vector. In the AdmATF-HSA injected group, the maximum was obtained at day 7 following injection, then decreased by day 11, and was still detectable 18 days after injection.
Adenovirus-mediated mATF-HSA gene transfer reduced CIA symptoms
The intravenous administration of 10 9 p.f.u. of Ad-mATF-HSA on day 25 following arthritis induction significantly decreased the incidence of the disease: 90% of animals in the control group (AdCO1) developed clinical signs of severe arthritis, compared with 40% of the Ad-mATF- HSA injected animals, P Ͻ 0.001 on day 45 (Figure 3a) . Treated animals had delayed arthritis, as the onset of the disease was on day 38.2 ± 4.4 in the Ad-mATF-HSA group compared with day 35.4 ± 4.5 in the control group, although it did not reach statistical significance (P > 0.05). As shown in Figure 3b , the severity of the disease, determined by the measure of paw swelling during the course of arthritis, was significantly worsened in the control virus-injected mice compared with the Ad-mATF-HSA-treated group from day 35 following arthritis induction (ie 10 days following adenovirus-mediated gene transfer). Paw widths were respectively increased by 1.81 ± 0.13 versus 1.70 ± 0.08 (P Ͻ 0.03). The number of paws with severe inflammation was increased in the controls compared with Ad-mATF-HSA-virus injected mice as shown Figure 3c .
Effects of mATF-HSA overexpression on angiogenesis.
The mechanisms responsible for the observed decrease in severity of CIA following Ad-mATF-HSA treatment were next investigated. First, we evaluated the effects of gene transfer on bone erosion in the ankles recovered from each group after death by radiological examination of the X-rays (Figure 4a ). The global X-ray score resulted from the addition of joint space narrowing, erosion and demineralization scores (maximal 9). On day 44, the ankles of Ad-mATF-HSA-injected mice showed less radiological features of severe joint destruction than controls, although it did not reach statistical significance ( Figure  4b) .
Second, the histological examination of arthritic joints from Ad-mATF-HSA-injected mice did not reveal differences in inflammatory synovitis, pannus formation and inflammatory cell infiltration, as opposed to the control (Figure 4c ). Third, paw sections were stained with Safranin-O to evaluate the possible role of the anti-angiogenic gene transfer on proteoglycan amounts in the cartilage matrix. After scoring the staining intensity on sections, marked reduction of staining was observed in the arthritic controls. In Ad-mATF-HSA-treated mice, no significant reduction of proteoglycan loss was found (data not shown).
Finally, since ATF has an EGF-like domain involved
Figure 4 Effect of Ad-mATF-HSA gene transfer on radiological and histological arthritic paw features. Mice were killed 18 days after Ad-mATF-HSA () or Ad-CO1 (ᮀ) gene delivery and ankle joints were taken for X-ray (a). Loss of bone substance, pinching and demineralization were scored (b). Ankles were processed for sections and HE staining for scoring of three histological parameters (c) as described in Materials and methods. Data are shown as mean ± s.d.
Gene Therapy in the inhibition of neovascularization, we assessed the number of vessels present in the inflamed synovium of the arthritic ankles through actin immunostaining ( Figure  5a and b). The number of vessels observed was significantly decreased in the synovial inflammatory tissue of Ad-mATF-HSA-treated mice compared with controls ( Figure 5c ).
Immune response to mATF-HSA gene transfer First, to determine whether the Ad-mATF-HSA treatment of CIA was associated with a modified humoral response to bovine collagen type-II, levels of anti-bCII antibodies produced during the course of arthritis were measured. Circulating titers for IgG1 and IgG2a isotypes against bCII were determined by ELISA in serum samples at different times after vector injection. We did not observe any modification in the IgG1 or IgG2a anti-bCII levels in sera of animals, whatever the injected virus (OD were respectively 0.8 and 0.78 in Ad-mATF-HSA-treated mice, versus 1.02 and 0.96 in controls). The Th2/Th1 (IgG1/IgG2a) responses were less than 1 during the CIA course, reflecting a more pronounced Th1 phenotype in both groups.
As we described below, the expression of the mATF-HSA protein was maximal in the sera of Ad-mATF-HSA treated animals 1 week after gene transfer, then decreased between day 7 and 11, and remained quite stable until death. To understand the decrease in protein expression, we assessed the immune response to the HSA component of the chimeric molecule by analyzing the presence of IgG anti-HSA in mice sera. We observed an increase in the anti-HSA IgG level in the Ad-mATF-HASinjected animals from day 11 after gene transfer until death ( Figure 6 ). These observations indicate that the anti-HSA antibodies induced after i.v. administration of the Ad-mATF-HSA vector are responsible for the decrease of the mATF-HSA serum level.
Discussion
Angiogenesis is a key step in rheumatoid arthritis, playing a central role in the initiation and persistence of the disease. 2, 18 Neovascularization inhibition in experimental arthritis models has been previously evaluated using various inhibitors, such as tranexamic acid inhibiting plasmin, 19 the cell surface-targeted plasmin inhibitor ATF-BPTI, 20 cyclopeptides antagonist of integrin ␣V␤3, a fumagillin derivative AGM-1470 toxic to proliferative endothelial cells, 7, 19 or a monoclonal antibody inhibiting VEGF. 9 All these data demonstrated the efficiency of antiangiogenic strategies in RA. Furthermore, the uPA receptor is highly expressed on synovial membrane, 10 and a considerable increase of uPA catalytic activity was observed in RA synovium. Overexpression of uPA/uPAR complex by synoviocytes might favor cell invasion by this tumor-like mass through the degradation of the cartilage matrix. 13 Therefore, we investigate the protective effect of the amino-terminal fragment of murine urokinase (mATF), an antagonist of the uPA/uPAR system, in a mice model for RA.
In this study, we demonstrated the inhibition of collagen-induced arthritis after systemic delivery of AdmATF-HSA. The overexpression of the anti-angiogenic factor was obtained by fusing mATF to the human serum albumin (mATF-HSA). A single i.v. administration of the adenoviral construct (10 9 p.f.u.) leads to expression of mATF-HSA in the mice serum with a maximum at 7 days following gene transfer, while the protein was undetectable after Ad-mATF gene delivery. The Ad-mATF-HSA treatment decreased the incidence and severity of the disease when injected 25 days after arthritis induction. The incidence of arthritis was lower (40% versus 90% in controls) and paw swellings were significantly inhibited compared with AdCO1 group (1.79 ± 0.12 mm versus 1.67 ± 0.08 mm on day 37, P Ͻ 0.02). Thus, the secretion of mATF-HSA-mediated by Ad-mATF-HSA vector before the arthritis onset protected against the subsequent progression of disease. Although the mATF-HSA levels detected in sera are strongly decreased on day 11 after gene transfer (ie 36 days after arthritis induction), the protective effect lasted until death (day 44, ie 19 days following virus delivery). A significant reduction in both clinical signs of arthritis, reflected by paw swelling, as well as a decrease in blood vessel number observed within the synovial inflammatory tissue, were observed in the Ad-mATF-HSA-treated group compared with controls. Our results showed that Ad-mATF-HSA treatment decreased angiogenesis in the arthritic paws, but did not modify cartilage erosion nor proteoglycan loss in the cartilage matrix or histopathology, as determined respectively by radiological and histopathological analysis of arthritic paws. This observation suggests that mATFGene Therapy HSA might be effective in arthritis by inhibiting synovial angiogenesis rather than inhibiting the synovial cells invasiveness. Because ATF does not play a role in the proliferation of T cells, the collagen-specific T cell proliferative status should not be influenced by the AdmATF-HSA treatment, and thus was not investigated in this study.
Since the formation of intra-articular neovessels facilitate joint infiltration by immune cells and tumor-like progression of the synovium, which are the earliest histopathological steps in RA pathogenesis, it was important to use an anti-angiogenic gene delivery before the onset of the disease, rather than after. Adenovirus-mediated ATF overexpression has been shown to decrease angiogenesis in a lung carcinoma mouse model. 15, 16 Since adenoviral gene transfer allowed high level production of therapeutic factors, we tested the Ad-mATF vector in the CIA mice model of arthritis. In our hands, mATF overexpression remained clinically inefficient (data not shown), but the short half-life of the molecule could explain the absence of a biological effect in this model. In contrast, a significant effect could be observed after coupling mATF to HSA. Moreover, we showed that HSA stabilization enhanced mATF bioavailability without altering its biological activity. HSA was chosen as a pharmacological carrier for the following reasons: (1) it is a long-lasting neutral carrier already used for macromolecular drugs; 21, 22 (2) it can escape the vascular compartment allowing access to disease tissue; and (3) it has previously been shown to increase the half-life of a 179-residue peptide in rabbits by 140-fold. 23 Our data showed that mATF-HSA-sustained expression inhibited synovial angiogenesis at the early phase of arthritis since the number of vessels observed in the inflamed paws was significantly decreased in Ad-mATF-HSA-treated animals. Van der Land et al 20 have recently evaluated a similar construct containing ATF gene in a SCID/hu model, where the human synovial cells are isolated and cultured in an inert sponge before implantation in the kidney capsule. They clearly demonstrated a decreased synovial cell invasion and cartilage matrix degradation. However, as reported by others, we were not able to demonstrate an effect on cartilage or bone erosion in inflamed paws.
There are drawbacks in using adenovirus vectors for gene therapy in arthritis. Gene therapy improves the delivery of therapeutic proteins and allows high but transient concentrations of therapeutic protein. This is due to the development of an immune response against adenoviral proteins and transgene expression. 24 Local intraarticular injections of adenovirus vector has been proposed, but this strategy induces inflammatory reactions in murine joints. We selected a systemic gene therapy strategy to avoid this limitation and to treat all inflamed joints from one animal. We did not observe any sideeffects related to systemic expression of mATF-HSA protein. However, we detected an immune response against HSA, assessed by the rise of IgG-HSA antibodies 11 days following Ad-mATF-HSA injection. The high titer of antibodies was associated with the decrease in mATF-HSA expression, suggesting that the immune response was responsible in part for the loss of biological efficiency. This is the first experiment to demonstrate angiogenesis inhibition in arthritis through in vivo gene therapy. Gene therapy delivery of the therapeutic factor was improved by fusing mATF to HSA, allowing high con-centrations of circulating anti-angiogenic protein, without altering its capacity to inhibit plasminogen activation. Taken together, our in vivo results argue for a beneficial therapeutic effect of delivering the mATF-HSA uPAR antagonist in the collagen-induced arthritis model. This approach can interfere with angiogenesis at the sites of arthritic joints and may lead to more effective strategies for RA treatment.
Materials and methods
Recombinant adenoviral vectors
Ad-mATF-HSA is a ⌬EI-⌬E3 recombinant adenovirus expressing the murine ATF coupled to HSA gene under the control of the immediate-early promoter of the cytomegalovirus (CMV). 16 The gene encoding the mATF-HSA genetic conjugate (745 residues) was generated by PCR amplification of the HSA and the mATF. This composite gene can be described from its 5Ј to 3Ј end by the succession of: (1) a NotI-BsaHI restriction fragment encoding the native secretion signal of murine urokinase (uPA) and the first 135 residues of mature murine uPA (mATF), immediately followed by a four Gly amino acid spacer; (2) genetically linked to a BsaHI-XhoI restriction fragment coding for the 586 residues of mature HSA.This genetic conjugate was cloned in the pCEP4 vector (Invitrogen) to add the CMV promoter and a polyA (SV40polyA). The obtained plasmid was called pCB20. A SalI-SalI fragment of pCB20 was then cloned in the shuttle vector pXL3048 linearized by SalI. pXL3048 is a KmR-SacB-ColE1 derivative containing the left end of the Ad5 genome (nucleotides 1-386) and a part of the Ad5 pIX gene (nucleotides 3446-4296). The shuttle vector containing the mATF-HSA expression cassette was called pCB21. The recombinant adenoviral genome was obtained by homologous recombination between plasmid pCB21 and pXL3215 in Escherichia coli, as described previously. 25 pXL3215 contains the Ad5 genome bordered by two PacI sites and carrying deletions within E1 (nucleotides 386-3446) and E3 (nucleotides 28 592-30 470). After recombinational cloning in E. coli, the adenoviral genome was excised by PacI digestion, and the AdmATF-HSA virus was recovered by transfecting 5 g of PacI-digested DNA into 293 cells by Lipofectamine Plus-based procedure (Life Technologies). The AdCO1 is a control virus that is identical to Ad-mATF-HSA, except that it does not carry the mATF-HSA expression cassette. High titer recombinant adenovirus samples were prepared by amplification in 293 cells and purified on CsCl gradients. Stock titers were determined on 911 cells hyplaque assays and are stated as plaque forming units/ml (p.f.u./ml). Vector particle numbers obtained by this method were equal or greater than 10 11 p.f.u./ml.
Inhibition of plasminogen activation
Murine colon carcinoma uPAR+ cells (C38) were infected at a multiplicity of infection (MOI) of 50 and 100 p.f.u./cell with Ad-CO1, Ad-mATF and Ad-mATF-HSA viruses for 40 h. Infected cells (3 × 10 5 ) were incubated at 4°C for 1 h in a C38-conditioned medium (supernatant of confluent C38 cells collected after 24 h of culture without fetal calf serum) that provides urokinase (uPA). Cells were washed with PBS, 0.1% BSA. Human plasminogen (7.5 g) was then added: uPA bound on its receptor uPAR activates plasminogen into plasmin. Plasmin generated was evaluated by its amidolytic activity plasminsensitive chromogenic substrate S-2251 (166 g added) (Chromogenix, Sweden). The paranitroanilin released from the substrate was measured by absorbance at 405 nm. Plasmin generation was calculated by comparison with a standard curve established with purified plasmin (Chromogenix, Sweden).
Collagen-induced arthritis
Male DBA1 mice were bred in our facilities and used at the age of 8-10 weeks. Bovine type II collagen (EPC, Owensville, USA) was diluted at 2 mg/ml in PBS, and emulsified with an equal volume of Freund's complete adjuvant (Pierce, Bezons, France) before use. CIA was induced by intradermal injection at the base of the tail with 100 l of solution (100 g collagen) at day 0. On day 21, the animals were boosted with one injection of 100 g type II collagen at 1 mg/ml in PBS. This resulted in the onset of CIA between days 30 and 32 as previously described. 26 Treatment of CIA Before the onset of arthritis, animals were divided into two groups. On day 25 after immunization, mice were injected i.v. with 10 9 p.f.u. of adenoviral vector expressing mATF-HSA (n = 10) or control vector (n = 10) in 100 l PBS. Blood samples were taken on days 0, 7, 11 and 18 following vector injection and stored at -20°C until tested.
Assessment of CIA
From day 21, the paw width was measured with a micrometer by an independent observer, without knowledge of the experimental groups. At day 44 mice were killed. Radiography of the hind paws was performed before fixation in 4% paraformaldehyde. Paws were then decalcified in DC3 (Labonord, Templemars, France), embedded in paraffin, and 2-m sections were stained with hematoxylin/eosin or Safranin-O/Fast green (Sigma, L'ile d'Abeau, France). Sections and X-rays were examined blindly. X-rays performed on Kodak films were scored for tibio-astragalus and tarsum joints from 0 to 3 for each of the following parameters: demineralization, narrowing and joint erosion. Two different areas of each paw (midfoot and hindfoot joints) were scored on successive sections for overall histopathological analysis as previously described. 27 The proteoglycan depletion determined by Safranin-O staining was scored on a scale of 0-3, ranging from full stained cartilage to destained cartilage. The level of anti-bcII antibodies (IgG1 and IgG2a) was determined in serum samples as previously described. 27 Immunostainings For vascularization assessement of murine paws, immunostaining was performed 1 h with a mouse antismooth muscle actin antibody (1/100, Dako). An isotypematched mAb IgG1 was used as control. The vessels were revealed with the UltraVision mouse tissue detection system anti-mouse HRP/DAB kit (Lab Vision Corporation, Fremont, CA, USA). Vessels were counted within the histological synovial tissue.
Immunoassay of mATF-HSA. Sera were collected from blood samples and stored at -20°C until tested. Circulating mATF-HSA levels were measured by ELISA for each individual on days 0, 7, 11 and 18. A 96-well microtiter plate (Nunc Maxisorb, Roskilde, Denmark) was coated with 500 ng/well of a rabbit anti-human albumin antibody (A0433, Sigma) diluted in PBS. After overnight incubation at 4°C, the wells were washed six times with TBST (Tris-buffered saline, 0,02% Tween 20) . Wells were blocked with TBSTM (TBST, 5% non-fat dry milk) for 3 h at room temperature on a rocking platform shaker. After being washed as above, wells were incubated with 50 l of serial dilutions of mice sera prepared in TBSTM. After a 2-h incubation with shaking and washing as above, wells were incubated 1 h at room temperature with 50 l of mouse anti-murine ATF antibody H77A10 (Molecular Innovations) diluted to 300 ng/ml in TBSTM. After washing, wells were incubated with 50 l of alkaline phosphatase-conjugated antibody raised against mouse IgG (Promega, Madison, WI, USA) diluted to 1:5000 in TBSTM. After incubation and washing as above, mATF-HSA was detected by a 20-min incubation in the dark with 50 l of developing solution (alkaline phosphatase substrate kit; BioRad Laboratories, Richmond, CA, USA). The absorbance was measured at 405 nm.
mATF-HSA immunoprecipitation and immunoblotting
Six hundred g of serum proteins were precipitated in Net-N buffer (50 mm Tris pH 7.5, 150 mm NaCl, 1 mm EDTA, 0.1% Nonidet NP40, 20% glycerol) with protein A-and protein G-Sepharose beads and 1 g of antimurine ATF antibody H77A10 overnight at 4°C. After five washes in Net-N, immunoprecipitates were collected by centrifugation. The precipitates were boiled in loading buffer and separated in 6% Tris-glycine gels. The protein transfer to nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany) was performed for 3 h with a semi-dry transfer system (BioRad, Hercules, CA, USA) and blocked 1 h in 5% milk TBS-T solution (Tris 1 mm pH 8, 150 mm NaCl, 0.05% Tween 20). Anti-murine ATF antibody H77A10 was applied overnight diluted to 1:4000 in 2% milk TBS-T solution supplemented with 0.1% sodium azide. After washing 1 h in TBS-T, secondary antibody (peroxidase-conjugated AffiniPure antimouse IgG; Jackson Immunoresearch, West Grove, PA, USA) was applied diluted to 1:20 000 in 2% milk TBS-T solution supplemented with 0.1% sodium azide for 30 min, and the membrane was rewashed against TBS-T for 1 h. Blotting was revealed using an ECL kit (Amersham, Buckinghamshire, UK).
Anti-HSA ELISA
The presence of HSA-specific antibodies in the sera was determined by ELISA. Microplates with 96 wells (Nunc) were coated with 100 ng of human albumin (A-8763, Sigma), and blocked with 5% milk in TBST-Tween. Serial dilutions of the sera were then added. Bound antibodies were detected with peroxidase-conjugated anti-mouse IgG (Jackson Immunoresearch Laboratories, West Grove, PA, USA) goat antibodies diluted to 1:5000. The peroxidase was revealed by incubation with the substrate ophenylenediamine dihydrochloride (Sigma) for 30 min. The reaction was stopped by addition of 3 N HCl, and a spectrophotometric reading was obtained at 490 nm.
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Statistics
Statistical significance was determined with a Fisher's exact test for contingency group comparisons, and unpaired t test or Mann-Whitney test as appropriate according to data distribution. P values of less than 0.05 were considered significant. All data were analyzed by Instat 2.01 software program for Macintosh.
